Analysis of Predictive Factors for Efficacy of Yiqi Yangxue Prescription Combined with Western Medicine in Treatment of Aplastic Anemia in Non-elderly Adults

ZHANG Chaochang; LI Rui; LIU Jian; DING Yubin; WANG Jinhuan; LIU Qifeng; XU Ruirong; WANG Haixia; DI Haixia; SUN Antao; XU Yonggang; YANG Xiupeng; LIU Feng; MA Rou; TANG Xudong

doi:10.13422/j.cnki.syfjx.20232027

您当前的位置：

首页 >

文章列表页 >

Analysis of Predictive Factors for Efficacy of Yiqi Yangxue Prescription Combined with Western Medicine in Treatment of Aplastic Anemia in Non-elderly Adults

更新时间：2023-09-21

- Analysis of Predictive Factors for Efficacy of Yiqi Yangxue Prescription Combined with Western Medicine in Treatment of Aplastic Anemia in Non-elderly Adults
  增强出版
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 29, Issue 20, Pages: 88-98(2023)
- 作者机构：
  
  1.中国中医科学院西苑医院，北京 100091
  2.中国中医科学院研究生院，北京 100700
  3.北京中医药大学研究生院，北京 100029
  4.深圳市中医院，广东深圳 518033
  5.黑龙江中医药大学附属第一医院，哈尔滨 150040
  6.吉林省人民医院，长春 130021
  7.山东中医药大学附属医院，济南 250011
  8.潍坊医学院附属医院，山东潍坊 261041
  9.廊坊市中医医院，河北廊坊 065000
  10.中国中医科学院广安门医院，北京 100053
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20232027
  CLC： R2-0;R22;R242;R287;R556.5
- Published：20 October 2023，
  
  Published Online：22 August 2023，
  
  Received：09 May 2023，
- 稿件说明：
扫描看全文
张朝畅,李芮,刘健等.益气养血方联合西药治疗非老年成人再生障碍性贫血疗效预测因素分析[J].中国实验方剂学杂志,2023,29(20):88-98.

ZHANG Chaochang,LI Rui,LIU Jian,et al.Analysis of Predictive Factors for Efficacy of Yiqi Yangxue Prescription Combined with Western Medicine in Treatment of Aplastic Anemia in Non-elderly Adults[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(20):88-98.
张朝畅,李芮,刘健等.益气养血方联合西药治疗非老年成人再生障碍性贫血疗效预测因素分析[J].中国实验方剂学杂志,2023,29(20):88-98. DOI： 10.13422/j.cnki.syfjx.20232027.

ZHANG Chaochang,LI Rui,LIU Jian,et al.Analysis of Predictive Factors for Efficacy of Yiqi Yangxue Prescription Combined with Western Medicine in Treatment of Aplastic Anemia in Non-elderly Adults[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(20):88-98. DOI： 10.13422/j.cnki.syfjx.20232027.

摘要

目的

探讨益气养血方联合西药治疗非老年成人再生障碍性贫血（AA）患者疗效的预测因素，为中医益气养血法联合西药治疗非老年成人AA提供预后参考。

方法

回顾性分析2018年9月至2021年3月就诊于中国中医科学院西苑医院等19家医院并采用益气养血方联合西药治疗的非老年成人AA患者的临床资料，根据治疗6个月的疗效评价结果分为有效组和无效组，分析两组患者在性别、年龄、疾病分型［非重型再障（NSAA）/重型再障（SAA）］、病程、家族史、合并症、药物过敏史、基线血常规［包括血红蛋白（HGB）、白细胞（WBC）、中性粒细胞（ANC）、血小板（PLT）及网织红细胞（Ret）］、T淋巴细胞亚群、骨髓有核细胞增生程度、T-bet及GATA-3基因指标上的差异。

结果

共纳入101例非老年成人AA患者，有效组81例，无效组20例。与无效组比较，有效组无药物过敏史患者占比更高（

0.05）；两组患者在身高、体质量、性别、年龄、分型、病程、家族史、合并症方面差异均无统计学意义。与无效组比较，有效组患者治疗前ANC、PLT水平更高（

0.05），有效组ANC≥1.6×10

个/L、PLT≥25×10

个/L的患者占比更高（

0.05，

0.01）；两组患者在WBC、HGB、Ret基线水平上无显著统计学差异。有效组患者治疗前CD3

HLA-DR

T细胞水平明显高于无效组（

0.05），两组患者治疗前CD3

CD19

T细胞、CD4

T细胞、CD8

T细胞、Th1细胞、Th2细胞、CD3

CD25

T细胞水平差异均无统计学意义。有效组患者治疗前骨髓有核细胞增生活跃患者占比明显高于无效组，增生减低、极度减低患者的占比明显低于无效组（

0.05）。两组患者治疗前T-bet、GATA-3基因表达水平差异均无统计学意义。多因素二元Logistic回归分析显示，治疗前ANC水平及药物过敏史是疗效的独立影响因素（

0.05，

0.01），其他指标均不是疗效的影响因素。应用ROC曲线分析治疗前ANC水平对益气养血方联合西药治疗非老年成人AA的预测价值，曲线下面积为0.679（

0.05），以1.595×10

个/L为临界值，灵敏度为0.42，特异度为0.95。

结论

药物过敏史、治疗前ANC、PLT、CD3

HLA-DR

T细胞水平、骨髓有核细胞增生程度是益气养血方联合西药治疗非老年成人AA患者疗效的预测因素；无药物过敏史，治疗前ANC、PLT水平更高，尤其是ANC≥1.6×10

个/L、PLT≥25×10

个/L及治疗前CD3

HLA-DR

T细胞水平更高，骨髓有核细胞增生更为活跃的非老年成人AA患者运用益气养血方联合西药治疗更易起效。

Abstract

Objective

To explore the predictive factors for the efficacy of Yiqi Yangxue prescription combined with western medicine in treating aplastic anemia （AA） in non-elderly adults， so as to provide a reference for predicting the prognosis of this therapy.

Method

A retrospective study was conducted with the clinical data of non-elderly adult AA patients who visited 19 hospitals including Xiyuan Hospital of the China Academy of Chinese Medical Sciences from September 2018 to March 2021 and were treated with Yiqi Yangxue Prescription combined with western medicine. According to the efficacy evaluation results at the 6

month of treatment， the patients were assigned into effective and ineffective groups. The two groups were compared in terms of the gender， age， disease classification ［non-severe aplastic anemia （NSAA）/severe aplastic anemia （SAA）］， course of disease， family history， complications， history of drug allergy， baseline blood routine examination ［hemoglobin （HGB）， white blood cell （WBC）， neutrophil （ANC）， platelet （PLT）， and reticulocyte （Ret）］， T lymphocyte subsets， degree of proliferation of nucleated cells in bone marrow， and expression of T-bet and GATA-3.

Result

A total of 101 non-elderly adult AA patients were enrolled in this study， including 81 in the effective group and 20 in the ineffective group. The effective group had a higher proportion of the patients without a history of drug allergy than the ineffective group （

0.05）. The body height， body weight， gender， age， disease classification， course of disease， family history， and complications showed no significant differences between two groups. The effective group had higher levels of ANC and PLT before treatment （

0.05） and higher proportion of patients with ANC≥1.6×10

/L and PLT≥25×10

/L （

0.05，

0.01） than the ineffective group. The baseline levels of WBC， HGB， and Ret showed no significant statistical differences between two groups. The levels of CD3

HLA-DR

T cells in the effective group before treatment was higher than that in the ineffective group

（

0.05）. The levels of CD3

CD19

T cells， CD4

T cells， CD8

T cells， Th1 cells， Th2 cells， and CD3

CD25

T cells showed no significant statistical differences between two groups before treatment. The proportion of patients with active bone marrow nucleated cells proliferation in the effective group before treatment were significantly higher than that in the ineffective group

while the proportion of patients with reduced or extremely reduced proliferation were significantly lower than that in the ineffective group （

0.05）. The expression levels of T-bet and GATA-3 genes had no significant differences between two groups before treatment. The multivariate binary logistic regression analysis showed that the ANC level before treatment and history of drug allergy were independent influencing factors for efficacy （

0.05，

0.01）， while other indicators were not influencing factors for efficacy. The receiver operating characteristic （ROC） curve was applied to analyze the predictive value of the ANC level before treatment in the treatment of AA in non-elderly adults with Yiqi Yangxue prescription combined with western medicine. The area under the curve was 0.679 （

0.05）， with the critical value of 1.595×10

/L， the sensitivity of 0.42， and the specificity of 0.95.

Conclusion

The history of drug allergy， pre-treatment ANC， PLT， CD3

HLA-DR

T cell levels， and proliferation of nucleated cells in bone marrow before treatment are predictive factors for the efficacy of Yiqi Yangxue prescription combined with western medicine in treating AA in non-elderly adults. This therapy tends to be more effective for the patients with no history of drug allergy， higher ANC and PLT levels before treatment， especially those with ANC≥1.6×10

/L， PLT≥25×10

/L， and higher CD3

HLA-DR

T cell levels and the more active proliferation of nucleated cells in bone marrow before treatment.

关键词

再生障碍性贫血益气养血方中西医结合治疗预测因素

Keywords

aplastic anemiaYiqi Yangxue prescriptiontreatment with integrated traditional Chinese and western medicinepredictive factors

references

中华医学会血液学分会红细胞疾病（贫血）学组. 再生障碍性贫血诊断与治疗中国指南（2022年版）［J］. 中华血液学杂志， 2022，（11）： 881-888.

YOUNG N S， KAUFMAN D W. The epidemiology of acquired aplastic anemia ［J］. Haematologica， 2008， 93（4）： 489-492.

MONTANE E， IBANEZ L， VIDAL X， et al. Epidemiology of aplastic anemia： A prospective multicenter study ［J］. Haematologica， 2008， 93（4）： 518-523.

KILLICK S B， BOWN N， CAVENAGH J， et al. Guidelines for the diagnosis and management of adult aplastic anaemia ［J］. Br J Haematol， 2016， 172（2）： 187-207.

杨丽，王素珍，王海霞.基于倾向指数匹配法的慢性再生障碍性贫血疗效评价研究［J］.中国卫生统计，2020，37（4）：614-616.

冀晓红，李草旎，杨学民，等. 中西医结合治疗慢性再生障碍性贫血的临床疗效及不良反应分析［J］. 中华中医药学刊， 2016， 34（12）： 3027-3029.

唐旭东，张姗姗，许勇钢，等. T细胞亚群在重型再生障碍性贫血治疗中的疗效预测价值［J］. 中医杂志， 2013， 54（20）： 1755-1758.

唐旭东，张姗姗，麻柔，等. 补肾中药为主的中西医结合治疗再生障碍性贫血的免疫学机制及疗效预测指标探讨［J］. 中华中医药杂志， 2012， 27（4）： 1101-1105.

唐旭东，刘锋，李柳，等. 以补肾中药为主联合抗淋巴细胞球蛋白/抗胸腺细胞球蛋白治疗重型再生障碍性贫血的预测因素［J］. 世界中医药， 2018， 13（4）： 813-817， 821.

HARTUNG H D， OLSON T S， BESSLER M. Acquired aplastic anemia in children ［J］. Pediatr Clin North Am， 2013， 60（6）： 1311-1336.

SCHEINBERG P， WU C O， NUNEZ O， et al. Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine ［J］. J Pediatr， 2008， 153（6）： 814-819.

沈悌，赵永强. 血液病诊断及疗效标准（第四版）［M］. 北京：科学出版社， 2018： 18-20.

郑筱萸. 中药新药临床研究指导原则（试行）［M］. 北京：中国医药科技出版社， 2002： 378-383.

沈自尹，王文健. 中医虚证辨证参考标准［J］. 中西医结合杂志， 1986 （10）： 598.

杨洁茹，王化泉，邵宗鸿.再生障碍性贫血发病机制的研究进展［J］.中华血液学杂志，2019，40（9）：796-800.

刘春燕，邵宗鸿. 再生障碍性贫血发病机制研究进展［J］. 中国实用内科杂志， 2016， 36（5）： 345-349.

LI B，LIU S，NIU Y，et al.Altered expression of the TCR signaling related genes CD3 and FcεRIγ in patients with aplastic anemia［J］.J Hematol Oncol，2012，5：6.

SCHOETTLER M L， NATHAN D G. The pathophysiology of acquired aplastic anemia： Current concepts revisited ［J］. Hematol Oncol Clin North Am， 2018， 32（4）： 581-594.

XING L， LIU C， FU R， et al. CD8+HLA-DR+T cells are increased in patients with severe aplastic anemia ［J］. Mol Med Rep， 2014， 10（3）： 1252-1258.

ZENG Y， KATSANIS E. The complex pathophysiology of acquired aplastic anaemia ［J］. Clin Exp Immunol， 2015， 180（3）： 361-370.

张红霞，吴广胜，郭蔚玲. 再生障碍性贫血患者血清Th1/Th2细胞及相关细胞因子和T细胞亚群变化及意义［J］. 海南医学院学报， 2016， 22（10）： 1024-1026， 1030.

SOLOMOU E E， REZVANI K， MIELKE S， et al. Deficient CD4+CD25+FOXP3+ T regulatory cells in acquired aplastic anemia ［J］. Blood， 2007， 110（5）： 1603-1606.

SHI J， GE M， LU S， et al. Intrinsic impairment of CD4+CD25+ regulatory T cells in acquired aplastic anemia ［J］. Blood， 2012， 120（8）： 1624-1632.

DE LATOUR R P， VISCONTE V， TAKAKU T， et al. Th17 immune responses contribute to the pathophysiology of aplastic anemia ［J］. Blood， 2010， 116（20）： 4175-4184.

YOUNG N S， CALADO R T， SCHEINBERG P. Current concepts in the pathophysiology and treatment of aplastic anemia ［J］. Blood， 2006， 108（8）： 2509-2519.

SCHEINBERG P， NUNEZ O， WEINSTEIN B， et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia ［J］. N Engl J Med， 2011， 365（5）： 430-438.

陈信义，麻柔，李冬云. 规范常见血液病中医病名建议［J］. 中国中西医结合杂志， 2009， 29（11）： 1040-1041.

蓝海，侯丽，郎海燕，等.常见血液病的中医分类与命名［J］.中医杂志，2019，60（9）：750-753，778.

GAO S M， LIU J S， WANG M， et al. Traditional uses， phytochemistry， pharmacology and toxicology of Codonopsis： A review ［J］. J Ethnopharmacol， 2018， 219： 50-70.

XIE Q， SUN Y， CAO L， et al. Antifatigue and antihypoxia activities of oligosaccharides and polysaccharides from Codonopsis pilosula in mice ［J］. Food Funct， 2020， 11（7）： 6352-6362.

杜航，何文生，胡红兰，等. 白术活性成分药理作用研究进展［J］. 江苏中医药， 2022， 54（5）： 76-80.

叶青，刘东升，王兰霞，等. 茯苓化学成分、药理作用及质量控制研究进展［J］. 中医药信息， 2023， 40（2）： 75-79.

谢瑞强，王长福.炙甘草化学成分和药理作用研究进展［J］.中医药信息，2023，40（4）：84-89.

冯伟科，胡琦，张亚楠，等.基于PI3K-Akt-FoxO信号通路的四物汤对小鼠骨髓基质细胞凋亡的影响［J］.时珍国医国药，2020，31（2）：304-307.

杨思琦. 补肾生血法与益气养血法治疗再障的临床观察及对Th1/Th2、T-bet和GATA-3的影响研究［D］. 哈尔滨：黑龙江中医药大学， 2020.

李芮，丁宇斌，王文儒，等. 补肾生血方治疗慢性再生障碍性贫血的临床疗效及对T细胞亚群、T-bet与GATA3表达的影响［J］. 中国实验方剂学杂志， 2022， 28（15）： 94-101.

PEFFAULT DE LATOUR R， TABRIZI R， MARCAIS A， et al. Nationwide survey on the use of horse antithymocyte globulins （ATGAM） in patients with acquired aplastic anemia： A report on behalf of the French Reference Center for Aplastic Anemia ［J］. Am J Hematol， 2018， 93（5）： 635-642.

SONG M K， CHUNG J S， JOO Y D， et al. Is the early cyclosporine A level predictive of the outcome of immunosuppressive therapy in severe aplastic anemia？［J］. Eur J Haematol， 2009， 83（1）： 72-78.

LIU L， DING L， HAO L， et al. Efficacy of porcine antihuman lymphocyte immunoglobulin compared to rabbit antithymocyte immunoglobulin as a first-line treatment against acquired severe aplastic anemia ［J］. Ann Hematol， 2015， 94（5）： 729-737.

LIU J， LU X Y， CHENG L， et al. Clinical outcomes of immunosuppressive therapy for severe aplastic anemia patients with absolute neutrophil count of zero ［J］. Hematology， 2019， 24（1）： 492-497.

BODDU P， GARCIA-MANERO G， RAVANDI F， et al. Clinical outcomes in adult patients with aplastic anemia： A single institution experience ［J］. Am J Hematol， 2017， 92（12）： 1295-1302.

张朝畅，刘健，王文儒，等. 补肾生血方联合西药治疗再生障碍性贫血早期疗效预测指标［J］.中国实验方剂学杂志， 2023， 29（14）： 64-72.

AFABLE M G， SHAIK M， SUGIMOTO Y， et al. Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia ［J］. Haematologica， 2011， 96（9）： 1269-1275.

唐晓文，邵景章，张学光，等.再生障碍性贫血患者外周血T细胞亚群检测［J］.中华血液学杂志，1997，18（4）：205-206.

张丽琴. 补肾生血法和益气养血法对照治疗再障的临床观察及对CD3+HLA-DR+细胞表达的影响［D］. 哈尔滨：黑龙江中医药大学， 2021.

唐旭东，麻柔，刘锋，等. 再生障碍性贫血CD3+CD25+和CD3+HLA-DR+ T细胞亚群的表达与中医辨证分型的相关性研究［J］. 中国中医基础医学杂志， 2006，12（11）： 850-852.

SOLOMOU E E， KEYVANFAR K， YOUNG N S. T-bet， a Th1 transcription factor， is up-regulated in T cells from patients with aplastic anemia ［J］. Blood， 2006， 107（10）： 3983-3991.

沈红石，任传路，陈海飞，等. T-bet、GATA-3与T细胞亚群在再障中的相关性研究［J］. 现代生物医学进展， 2012， 12（9）： 1677-1679.

DUTTA A， DE R， DOLAI T K， et al. Changes in different cytokines （IL-2， TNF-α， and IFN-γ） profile in acquired aplastic anemia patients： A study from eastern India ［J］. J Pediatr Hematol Oncol， 2020， 42（3）： 185-192.

牟晓艳，常红，刘霆，等. 重型再生障碍性贫血免疫抑制治疗疗效预测指标的研究［J］. 四川大学学报：医学版， 2009， 40（5）： 897-900.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Changes of Immunological Indexes and Blood Routine in Treatment of Aplastic Anemia by Yiqi Yangxue Prescription

Early Efficacy Predictors of Bushen Shengxue Prescription Combined with Western Medicine in Treatment of Aplastic Anemia

Comparison of Blood Routine Changes in Treatment of Aplastic Anemia by Kidney-tonifying and Blood-generating Method and Qi-promoting and Blood-nourishing Method and Mode of Treatment by Stages

Bushen Jianpi Prescription Regulates Autophagy in Patients with Aplastic Anemia

Related Author

ZHANG Yaoyin

ZHANG Chaochang

HE Jiaqi

WANG Wenru

XU Ruirong

WAN Jiangwei

LIU Qifeng

SUN Antao

Related Institution

Affiliated Hospital of Shandong University of TCM

Dongfang Hospital，Beijing University of Chinese Medicine

Graduate School of China Academy of Chinese Medical Sciences

Graduate School of Beijing University of Chinese Medicine

Guang'anmen Hospital，China Academy of Chinese Medical Sciences

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰